291775-59-2

Basic information

• Product Name: (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid
• Synonyms: (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid;(1R,3S,4S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid;2-Azabicyclo[2.2.1]heptane-2,3-dicarboxylic acid, 2-(1,1-diMethylethyl) ester, (1R,3S,4S)-;(1R,3S,4S)-N-(Tert-butoxycarbonyl)-2-azabicyclo-[2.2.1]-heptane-3-carboxylic acid;(1R,3S,4S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid 97%;(1R,3S,4S)-3-[(2-methylpropoxy)carbonyl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid;Ledipasvir INT 2
• CAS NO: 291775-59-2
• Molecular Formula: C12H19NO4
• Molecular Weight: 241.28
• Product Categories: Pharmaceuticalintermediates
• Mol File: 291775-59-2.mol
• Article Data: 39

Chemical Properties

• Melting Point: 147-152 °C
• Boiling Point: 371.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.232±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.05±0.20(Predicted)
• CAS DataBase Reference: (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid(291775-59-2)
• EPA Substance Registry System: (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid(291775-59-2)

Safety Data

• Hazard Codes: Xi,N
• Statements: 61-36/37/38
• Safety Statements: 53-26-61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 291775-59-2(Hazardous Substances Data)

Usage

General Description

(3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid is a chemical compound with a complex molecular structure. It belongs to the class of carboxylic acids and contains a bicyclic ring system. The prefix "N-Boc" indicates the presence of a Boc (tert-butoxycarbonyl) protecting group attached to the nitrogen atom. (3S)-N-Boc-2-azabicyclo[2.2.1]heptane-3-carboxylic acid is a chiral molecule, with the (3S) configuration indicating the absolute configuration of the stereocenter at the third position on the bicyclic ring system. It may have applications in organic synthesis, medicinal chemistry, or material science due to its unique structure and properties.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 171754-02-2 (1S,3S,4R)-2-azabicyclo<2.2.1>heptane-3-carboxylic acid 
• 542-92-7 cyclopenta-1,3-diene 
• 204327-17-3 (1S,3R,4R)-2-aza-bicyclo<2.2.1>heptane-3-carboxylic acid ethyl ester 
• 88260-08-6 2-azabicyclo[2.2.1.]heptane-3-carboxylic acid,ethyl ester 
• 171754-03-3 (1S,3R,4R)-2-aza-bicyclo-[2.2.1]-heptane-3-carboxylic acid 
• 26250-84-0 (S)-(-)-1-(tert-butoxycarbonyl)-2-piperidinecarboxylic acid 
• 81357-21-3 ethyl (+/-)-N-tert-butyloxycarbonyl-2-azanorborn-5-ene-3-exo-carboxylate 
• 188057-42-3 ethyl (1R,3S,4S)-2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]heptane-3-carboxylate 
• 134984-63-7 (1S,3S,4R)-2-((R)-1-phenyl-ethyl)-2-aza-bicyclo[2.2.1]hept-5-ene-3-carboxylic acid ethyl ester 
• 1181573-36-3 (1R,3S,4S)-2-azabicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester 
• 220093-41-4 (1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carboxylic acid methyl ester 
• 130194-96-6 (1S,3S,4R)-2-[(1R)-1-phenylethyl]-2-azabicyclo[2.2.1]hept-5-ene-3-carboxylic acid methyl ester 
• 171754-02-2 (1S,3S,4R)-2-azabicyclo<2.2.1>heptane-3-carboxylic acid 

Downstream Products

• 1428666-14-1 (1R, 3S, 4S)-tert-butyl 3-((S)-1-amino-3-(4-iodophenyl)-1-oxopropan-2-ylcarbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1428666-16-3 (1R, 3S, 4S)-tert-butyl 3-((S)-2-(4-azidophenyl)-1-cyanoethylcarbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1428667-77-9 C₂₂H₂₈N₄O₄ 
• 1428666-30-1 C₂₁H₂₈BrN₃O₄ 
• 1428666-13-0 (1R,3S,4S)-tert-butyl 3-((S)-1-cyano-2-(4-iodophenyl)ethylcarbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256393-27-7 3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1256387-87-7 (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256387-74-2 (1R,3S,4S)-3-(6-bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256387-73-1 3-(2-amino-4-bromo-phenylcarbamoyl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1256383-53-5 (1R,3S,4S)-3-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1256387-76-4 (1R,3S,4S)-tert-butyl 3-(6-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1Himidazol-5-yl)biphenyl-4-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256387-75-3 (1R,3S,4S)-tert-butyl 3-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256387-78-6 methyl (S)-1-((S)-2-(5-(4'-(2-((1R,3S,4S)-2-((S)-2-(acetoxyamino)-3-methylbutanoyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)biphenyl-4-yl)-1Himidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 

Relevant articles and documents

Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)

Compounds that contain (R)-3-amino-4-(2,4,5-trifluorophenyl)butanoic acid substituted with bicyclic amino moiety (2-aza-bicyclo[2.2.1]heptane) were designed using molecular modelling methods, synthesised, and found to be potent DPP-4 (dipeptidyl peptidase-4) inhibitors. Compound 12a (IC50 = 16.8 ± 2.2 nM), named neogliptin, is a more potent DPP-4 inhibitor than vildagliptin and sitagliptin. Neogliptin interacts with key DPP-4 residues in the active site and has pharmacophore parameters similar to vildagliptin and sitagliptin. It was found to have a low cardiotoxic effect compared to sitagliptin, and it is superior to vildagliptin in terms of ADME properties. Moreover, compound 12a is stable in aqueous solutions due to its low intramolecular cyclisation potential. These findings suggest that compound 12a has unique properties and can act as a template for further type 2 diabetes mellitus drug development.

COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

ETHER COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.